ADMA Biologics Inc. (NASDAQ: ADMA) is 8.72% higher on its value in year-to-date trading and has touched a low of $1.45 and a high of $4.65 in the current 52-week trading range. The ADMA stock was last observed hovering at around $2.14 in the last trading session, with the day’s loss setting it -0.02% off its average median price target of $9.00 for the next 12 months. It is also 80.73% off the consensus price target high of $11.00 offered by 6 analysts, but current levels are 64.67% higher than the price target low of $6.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $2.12, the stock is 0.57% and 5.19% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.56 million and changing -0.93% at the moment leaves the stock -17.44% off its SMA200. ADMA registered -52.99% loss for a year compared to 6-month loss of -23.19%. The firm has a 50-day simple moving average (SMA 50) of $2.0575 and a 200-day simple moving average (SMA200) of $2.4267.
The stock witnessed a -4.50% gain in the last 1 month and extending the period to 3 months gives it a -14.86%, and is 0.47% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.06% over the week and 5.85% over the month.
ADMA Biologics Inc. (ADMA) has around 313 employees, a market worth around $201.40M and $40.30M in sales. Distance from 52-week low is 46.21% and -54.41% from its 52-week high.
ADMA Biologics Inc. (ADMA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ADMA Biologics Inc. (ADMA) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ADMA Biologics Inc. is expected to release its quarterly report on 05/07/2021 and quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $12.05M over the same period.The EPS is expected to grow by 38.90% this year, but quarterly earnings will post 37.40% year-over-year. Quarterly sales are estimated to grow 0.10% in year-over-year returns.
ADMA Biologics Inc. (ADMA) Top Institutional Holders
130 institutions hold shares in ADMA Biologics Inc. (ADMA), with 2.02M shares held by insiders accounting for 2.13% while institutional investors hold 55.70% of the company’s shares. The shares outstanding are 87.70M, and float is at 70.91M with Short Float at 16.88%. Institutions hold 54.51% of the Float.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 16.58 million shares valued at $39.64 million. The investor’s holdings represent 17.54% of the ADMA Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 5.47 million shares valued at $13.08 million to account for 5.79% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.64 million shares representing 3.85% and valued at over $8.7 million, while Marshall Wace LLP holds 2.63% of the shares totaling 2.49 million with a market value of $5.95 million.
ADMA Biologics Inc. (ADMA) Insider Activity
A total of 17 insider transactions have happened at ADMA Biologics Inc. (ADMA) in the last six months, with sales accounting for 0 and purchases happening 17 times. The most recent transaction is an insider purchase by DEMSKI MARTHA J, the company’s Director. SEC filings show that DEMSKI MARTHA J bought 2,200 shares of the company’s common stock on Sep 11 at a price of $2.29 per share for a total of $5038.0. Following the purchase, the insider now owns 4200.0 shares.
ADMA Biologics Inc. disclosed in a document filed with the SEC on Sep 10 that Grossman Jerrold B (Director) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Sep 10 and was made at $2.22 per share for $11100.0. Following the transaction, the insider now directly holds 0.16 million shares of the ADMA stock.
Still, SEC filings show that on Sep 08, Mond James (EVP, CSO and CMO) acquired 4,000 shares at an average price of $2.20 for $8800.0. The insider now directly holds 73,174 shares of ADMA Biologics Inc. (ADMA).
ADMA Biologics Inc. (ADMA): Who are the competitors?
The company’s main competitors (and peers) include CEL-SCI Corporation (CVM) that is trading 71.08% up over the past 12 months. Short interest in the company’s stock has fallen -2.17% from the last report on Nov 12, 2020 to stand at a total of 12.23 million short shares sold with a short interest ratio of 3.45.